Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression-Reference-Cited by-同舟云学术

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

Published:2021-05 Issue:3 Volume:22 Page:201-209
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

White Maya N,Piotrowska Zofia,Stirling Kevin^ORCID,Liu Stephen V,Banwait Mandeep K,Cunanan Kristen,Sequist Lecia V,Wakelee Heather A,Hausrath Daniel,Neal Joel W

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

2. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

3. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer;Reungwetwattana;J Clin Oncol,2018

4. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses;Mok;J Clin Oncol,2017

5. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3);Wu;J Clin Oncol,2018

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis;ESMO Open;2024-09

2. Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non–small cell lung cancer: a retrospective controlled real-world study;Frontiers in Oncology;2024-07-16

3. Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC;Lung Cancer;2024-07

4. Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World;The Oncologist;2024-03-23

5. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study;Annals of Oncology;2024-01